The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan

Lack of renoprotective effects of targeting the endothelin A receptor and/or sodium glucose transporter 2 in a mouse model of type 2 diabetic kidney disease

(2022) Deborah C Stuart et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

(2022) J. David Smeijer et al.   JACC-Heart Failure

Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis

(2022) Milton Packer   CIRCULATION

Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice

(2022) Ander Vergara et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

(2022) Niels Jongs et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The SONAR study—is there a future for endothelin receptor antagonists in diabetic kidney disease?

(2020) Avivit Cahn et al.   Annals of Translational Medicine

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction

(2020) Hiddo J.L. Heerspink et al.   KIDNEY INTERNATIONAL

Endothelins in cardiovascular biology and therapeutics

(2019) Neeraj Dhaun et al.   Nature Reviews Cardiology

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

(2019) Hiddo J L Heerspink et al.   LANCET

Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects

(2019) Motoaki Sano et al.   CIRCULATION

Dapagliflozin: A Review in Type 2 Diabetes

(2019) Sohita Dhillon   DRUGS

Endothelin ET A Receptor Blockade, by Activating ET B Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention

(2017) Magali Vercauteren et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Fluid Volume Overload and Congestion in Heart Failure

(2016) Wayne L. Miller   Circulation-Heart Failure

Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy

(2016) Margien G.S. Boels et al.   DIABETES

Plasma endothelin-1 level, measured glomerular filtration rate and effective renal plasma flow in diabetic nephropathy

(2015) Radmila Žeravica et al.   RENAL FAILURE

Plasma Pro-Endothelin-1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism

(2015) N. Dhaun et al.   Journal of the American Heart Association

Endothelin Blockade in Diabetic Kidney Disease

(2015) Lidia Anguiano et al.   Journal of Clinical Medicine

Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist

(2014) J. Hoekman et al.   Clinical Journal of the American Society of Nephrology

Endothelin and endothelin antagonists in chronic kidney disease

(2014) Donald E Kohan et al.   KIDNEY INTERNATIONAL